| University of Iowa Research Foundation Patent applications |
| Patent application number | Title | Published |
|---|
| 20130065298 | siRNA-MEDIATED GENE SILENCING - The present invention is directed to small interfering RNA molecules (siRNA) targeted against an allele of interest, and methods of using these siRNA molecules. | 03-14-2013 |
| 20130065296 | BACULOVIRUSES WITH ENHANCED VIRION PRODUCTION AND A METHOD FOR THE PRODUCTION OF BACULOVIRUSES - A method of co-expressing a portion of the VSV G protein gene or a truncated “stem” portion with GP64 and a retrovirus increases the titer of retroviral vectors. A truncated VSV G protein, preferably comprised of a small segment from the C-terminal portion of the ectodomain plus the transmembrane (TM) and cytoplasmic tail (CTD) domains of VSV G, co-expressed with retroviral vectors, enhances the production titers of the retroviral vectors. A preferred embodiment uses a VSV G construct that includes an N-terminal c-Myc epitope plus 42 amino acids from the C-terminal portion of the ectodomain, 20 amino acids from the predicted TM domain, and 29 amino acids from the predicted CTD of the VSV G protein. | 03-14-2013 |
| 20130034496 | POSITRON EMISSION TOMOGRAPHY TRACER - The present invention relates to positron emission tomography tracers and methods of using these tracers. | 02-07-2013 |
| 20130033739 | ELECTROVARIABLE NANOPLASMONICS AND SELF-ASSEMBLING SMART MIRRORS - Systems and methods provide control of nanoparticle coverage of an interface between a first medium and a second medium through variation of an electric potential across such interface; the first medium and the second medium are immiscible media, and transparent or substantially transparent to visible light. The first medium can be a first electrolytic solution and the second medium can be a second electrolytic solution; thus, the interface can become an interface of two immiscible electrolytic solutions (ITIES). The nanoparticle coverage of the interface, e.g., the ITIES, can be regulated to vary between approximately zero and a full or nearly a full monolayer. The nanoparticle coverage of the interface can dictate at least one optical property of the interface, rendering the interface transparent or substantially transparent, or a mirror, or providing Faraday rotation of the optical polarization of light incident normal to the interface and propagating through the interface. | 02-07-2013 |
| 20130020262 | HIGH-DENSITY POLYDICYCLOPENTADIENE - The invention provides highly cross-linked polydicyclopentadiene matrices and methods for using such matrices to separate components having varying cross-sectional areas. | 01-24-2013 |
| 20130012568 | Kits for Detecting Direct Oxidation of Calcium/Calmodulin Dependent Protein Kinase II and Associated Diagnostic and Therapeutic Methods - Calcium/calmodulin dependent protein kinase II (CaMKII) has been found to be directly oxidized, and direct oxidation of CaMKII was observed to result in calcium independent activation of CaMKII. Antibodies that bind specifically to oxidized forms of CaMKII (oxCaMKII) were generated and were utilized to detect oxCaMKII in blood from: (1) mice with cancer; (2) mice with a knock out of the gene encoding methionine sulfoxide reductase; (3) mice injected with angiotensin II; (4) mice injected with bacterial endotoxin; (5) mice fed a pro-oxidant (ketogenic) diet; and (6) mice with cancer that had been treated with experimental therapy. | 01-10-2013 |
| 20120297495 | ZINC-FINGER NUCLEASE AND RNA INTERFERENCE MEDIATED INACTIVATION OF VIRAL GENOMES - Embodiments of the present invention provide methods for targeted inactivation of viral genomes. In one embodiment, zinc-finger proteins in which DNA binding sites are altered such that they recognize and bind different, desired DNA sequences contained in hepatitis B virus (HBV) and that include nuclease domains are used for inactivation. Other embodiments for targeted inactivation of viral genomes use small nucleic acid molecules, such as short micro-RNA molecules or short hairpin RNA molecules capable of mediating RNA interference (RNAi) against the hepatitis B virus. | 11-22-2012 |
| 20120283424 | REDUCTION OF OFF-TARGET RNA INTERFERENCE TOXICITY - The present invention is directed to RNA interference (RNAi) molecules targeted against a nucleic acid sequence, and methods of using these RNAi molecules to reduce off-target toxicity. | 11-08-2012 |
| 20120277323 | CELLULOSE CAPSULES AND METHODS FOR MAKING THEM - Disclosed are cellulose capsules, methods for preparing a cellulose capsule, and compositions comprising cellulose capsules, including sustained- or controlled-release dosage forms comprising cellulose capsules. | 11-01-2012 |
| 20120195926 | METHODS OF IMPROVING VACCINE IMMUNOGENICITY - The present invention provides a process called “Immune Banking” that enhances vaccine efficacy by exploiting existing humoral responses. The process involves tagging new antigens with molecular markers recognized by an existing anti-body response. This recognition of the tagged vaccine components enhances adaptive immune responses to the new vaccine. | 08-02-2012 |
| 20120142583 | Methods of inhibiting and treating bacterial biofilms by metal chelators - The invention presented herein provides methods and compositions for the prevention and treatment of bacterial infections. The methods are based on the discovery that depletion of bioavailable iron stimulates surface motility in bacteria thus inhibiting the ability of a bacterial population to develop into a biofilm. | 06-07-2012 |
| 20120108514 | LONG ACTING ATRIAL NATRIURETIC PEPTIDE (LA-ANP) AND METHODS FOR USE THEREOF - Materials and Methods related to making and using natriuretic polypeptides having a mutation that results in an extended carboxy terminus. | 05-03-2012 |
| 20120095089 | SCHWEINFURTHINS AND USES THEREOF - Disclosed is a method for preventing or treating an undesirable condition in a subject carrying cells homozygous null for the neurofibromatosis type 1 gene or subjects that are haploinsufficient for the neurofibromatosis type 1 gene, the method comprising administering to a subject in need thereof an effective amount of a schweinfurthin or schweinfurthin analog or derivative, or a pharmaceutically acceptable salt, prodrug, hydrate, or solvate thereof. Also disclosed is a new schweinfurthin compound of the formula. | 04-19-2012 |
| 20120071356 | Variants in Complement Regulatory Genes Predict Age-Related Macular Degeneration - Methods for identifying a subject at risk for developing AMD are disclosed, as are kits which can be used to practice the methods. The methods include identifying specific protective or risk polymorphisms or genotypes from the subject's genetic material, including polymorphisms in the BF, C2 and/or CFH genes. Microarrays and kits for use in these methods are also provided. | 03-22-2012 |
| 20120069299 | HYBRID LASER OPHTHALMOSCOPE - Provided is a hybrid laser ophthalmoscope comprising a laser light source, a LED light source, and a holographic diffuser, wherein the holographic diffuser is configured to shape a beam of light into a Maxwellian ring. | 03-22-2012 |
| 20120040884 | Methods and Reagents for Treatment and Diagnosis of Vascular Disorders and Age-Related Macular Degeneration - Disclosed are screening methods for determining a human subject's propensity to develop a vascular disorder and/or age-related macular degeneration (AMD), therapeutic or prophylactic compounds for treating disease or inhibiting its development, and methods of treating patients to alleviate symptoms of the disease, prevent or delay its onset, or inhibit its progression. The inventions are based on the discovery that persons with a genome having a deletion of the CFHR-1 and/or CFHR-3 gene, which normally lie on human chromosome 1 between DNA encoding CFH and CFHR-4, are at reduced risk of developing AMD, and elevated risk of developing vascular disease such as aneurysm. | 02-16-2012 |
| 20120035320 | POLYACRIDINE NUCLEIC ACID DELIVERY PEPTIDE COMPLEXES - The present invention provides nucleic acid delivery polyplex complexes and anionic open polyplexes comprising a nucleic acid molecule reversibly bound to one or more of nucleic acid delivery polyplex complexes. | 02-09-2012 |
| 20120027673 | SYNTHESIS OF HIERARCHICAL NANOCRYSTALLINE ZEOLITES WITH CONTROLLED PARTICLE SIZE AND MESOPOROSITY - A one step synthesis of nanocrystalline zeolites ZSM-5 and Naβ from a single template system in high yield has been discovered. The size of individual nanocrystals, as well as mesopore surface area and pore volume can be controlled by adjusting the pH of the reaction mixture, as well as the hydrothermal treatment temperature and duration. The mesopore volume and size distribution show a dependence on particle size such that smaller particles lead to higher mesopore volumes and narrower pore size distributions. | 02-02-2012 |
| 20120015396 | COMPOSITIONS AND METHODS FOR MODULATING THE ACID-SENSING ION CHANNEL (ASIC) - Novel compositions for modulating acid-sensing ion channels (ASIC) function comprising ASICα, ASICβ, and BNC1 and derivatives thereof; methods for modulating ASIC function and methods for treating cognitive disorders and for memory enhancement using the novel compositions of the invention; and a method for increasing synaptic plasticity are described. | 01-19-2012 |
| 20120014875 | NUCLEIC ACID APTAMERS - The present invention relates to optimized aptamers and methods of using these aptamers. | 01-19-2012 |
| 20110319481 | SCHWEINFURTHIN ANALOGUES - Methods and intermediates for preparing enantiomerically enriched Schweinfurthin analogs which are useful for the treatment of cancer, as well as novel Schweinfurthin analogs having anti-cancer activity, compositions comprising such analogs and therapeutic methods comprising administering such analogs. | 12-29-2011 |
| 20110318735 | REGULATION OF THE SEROTONIN REUPTAKE TRANSPORTER AND DISEASE - Described herein is a CpG island in the 5′ region of the 5HTT gene that contains an alternative exon 1 and promoter for 5HTT. Methylation at this CpG island is associated with decreased levels of 5HTT mRNA, and this effect is evident when 5HTTLPR genotype is taken into account. Thus, this methylation status indicates 5HTT mRNA production, which serves as an indicator for the expression of the transporter and of a subject's vulnerability to diseases related to serotonergic activity. Accordingly, certain embodiments of the present invention provide diagnostic methods for determining whether a subject has, or is at risk for developing, a disease associated with serotonergic activity. | 12-29-2011 |
| 20110301580 | METHODS AND DEVICES FOR ARYTENOID REPOSITIONING - Methods and devices for repositioning the arytenoid cartilage of a human subject are disclosed. | 12-08-2011 |
| 20110260278 | System and Method of Planar Processing of Semiconductors into Detector Arrays - An article of manufacture and a method of defining a photodetector element are provided. The article of manufacture includes a photodector element comprising a junction formed by a first III-V semiconductor layer having a first charge type and a second III-V semiconductor layer comprising a second dopant having a second charge type. The second III-V semiconductor layer is disposed between the first III-V semiconductor layer and a wafer. Patterned dopant regions having a third charge type, the third charge type being the same as the first charge type, are disposed in the first III-V semiconductor layer. | 10-27-2011 |
| 20110253151 | POSITIONING DEVICE FOR ANKLE JOINT REPLACEMENT SURGERY - A positioning device for ankle joint replacement surgery. | 10-20-2011 |
| 20110244562 | RNA INTERFERENCE SUPPRESSION OF NEURODEGENERATIVE DISEASES AND METHODS OF USE THEREOF - The present invention is directed to RNA interference (RNAi) molecules targeted against a nucleic acid sequence that encodes poly-glutamine repeat diseases, and methods of using these RNAi molecules. | 10-06-2011 |
| 20110244561 | siRNA-MEDIATED GENE SILENCING - The present invention is directed to small interfering RNA molecules (siRNA) targeted against an allele of interest, and methods of using these siRNA molecules. | 10-06-2011 |
| 20110237645 | USE OF RNAi TECHNOLOGY TO INHIBIT ASIC3 - In vitro studies using cells transfected with acid-sensing ion channel 3 (ASIC3) or acid-sensing ion channel 1 (ASIC1) cDNA, demonstrated that the miRNAs against mouse ASIC3 (miR844 and miR847) selectively inhibit mouse ASIC3, but not ASIC1 as detected by protein expression and responses to pH. When the RNAi agents, miR844 or miR847, were used in vivo, delivered into the muscle of mice using a replication-defective herpes simplex viral (HSV-1) vector, primary and secondary hyperalgesia were reduced after carrageenan-induced muscle inflammation. Accordingly, the present invention provides RNAi agents that target ASIC3, methods of preparing such RNAi agents, and methods of using them to modulate in a cell the level of ASIC3 or activity of an ASIC including at least one ASIC3. Modulation of ASIC3 activity or levels can be used for different purposes such as treating pain associated with the expression of ASIC3 and the like. | 09-29-2011 |
| 20110212520 | RNA INTERFERENCE SUPPRESSION OF NEURODEGENERATIVE DISEASES AND METHODS OF USE THEREOF - The present invention is directed to small interfering RNA molecules (siRNA) targeted against nucleic acid sequence that encodes huntingtin or ataxin-1, and methods of using these siRNA molecules. | 09-01-2011 |
| 20110207190 | METHODS OF XYLITOL PREPARATION - The invention provides spray-dried preparations of microbes useful for oxidoreductase reactions, e.g., xylitol production, and methods of making and using those microbes. | 08-25-2011 |
| 20110206773 | SUSTAINED DELIVERY OF DRUGS FROM BIODEGRADABLE POLYMERIC MICROPARTICLES - Biodegradable polymeric microparticle compositions containing one or more active agents, especially those useful for treating or preventing or one or more diseases or disorders of the eye, and methods of making and using thereof, are described. The microsphere compositions release an effective amount of the one or more active agents for a period greater than 14 days in vivo, preferably greater than 60 days in vivo, more preferably up to 73 days in vivo, more preferably greater than 90 days in vivo, even more preferably over 100 days in vivo, and most preferably greater than 107 days in vivo. In a preferred embodiment, the microparticle compositions contain one or more active agents such as AG1478 to induce nerve regeneration, specifically regeneration of the optic nerve useful for managing elevated intraocular pressure (TOP) in the eye. | 08-25-2011 |
| 20110182908 | Diagnostics and Therapeutics for Macular Degeneration-Related Disorders - The invention relates to methods for treating, preventing and diagnosing macular degeneration-related disorders. | 07-28-2011 |
| 20110166687 | METHOD FOR DETERMINING THE PRODUCTION PARAMETERS FOR A SUBSTRATE COATING PROCESS - A method to evaluate, determine and optimize production parameters for a coating application of a UV cationic polymerizable coating system to a substrate is provided. The method is based on a simulation model which includes both shadow and dark cure processes. Both of an active center generation process and the active center diffusion process are mathematically described. In the model, the two processes are considered separately since they are driven by different fundamental phenomena and occur on different timescales. Evaluation or prediction of the effect of process variables on the curing of a cationic coating of a complex substrate according to the described method allows characterization and understanding of process variables which may save set-up costs and improve production efficiency. | 07-07-2011 |
| 20110166081 | Alpha-dystroglycan as a Protein Therapeutic - Disclosed is alpha-dystroglycan protein (alpha-DG) in glycosylated and functional form. The disclosed alpha-DG binds to the basal lamina and to the sarcolemma of muscle fibers and may be injected into muscle and incorporated into muscle fibers in order to restore membrane integrity where the muscle fibers comprise a dysfunctional alpha-DG protein. Alpha-DG as disclosed herein may be utilized in pharmaceutical compositions and methods for treating diseases and disorders associated with or characterized by a dysfunctional alpha-DG, such as muscular dystrophy. | 07-07-2011 |
| 20110160297 | SCHWEINFURTHIN ANALOGUES - The invention provides fluorescent schweinfurthin analogs of formula(I) which are useful as probes and for the treatment of cancer and other diseases. | 06-30-2011 |
| 20110160219 | Inhibitors of Phosphodiesterase Type 5A for Treating or Preventing Muscle Disease or the Symptoms Thereof in a Patient - Disclosed are pharmaceutical compositions and methods for treating or preventing muscle diseases or the symptoms thereof. The compositions typically include and the methods typically utilize phosphodiesterase type 5A inhibitors. | 06-30-2011 |
| 20110152172 | Methods of Treating Pulmonary Diseases and Disorders by Modulating Calcium/Calmodulin Dependent Protein Kinase II Activity - Disclosed are methods of treating or preventing a pulmonary disease or disorder in a subject, the methods comprising administering an effective amount of an compound that inhibits Calmodulin Kinase II (CaMKII) activity, either directly or indirectly, thereby treating or preventing the pulmonary disease or disorder in the subject. | 06-23-2011 |
| 20110135689 | Vaccine, therapeutic composition and methods for treating or inhibiting francisella tularenis - The present invention is directed to compounds and methods for treating a mammal exposed to | 06-09-2011 |
| 20110111491 | RNA INTERFERENCE SUPPRESION OF NEURODEGENERATIVE DISEASES AND METHODS OF USE THEREOF - The present invention is directed to small interfering RNA molecules (siRNA) targeted against nucleic acid sequence that encodes huntingtin or ataxin-1, and methods of using these siRNA molecules. | 05-12-2011 |
| 20110081366 | IMMUNOSTIMULATORY NUCLEIC ACID MOLECULES - Nucleic acid sequences containing unmethylated CpG dinucleotides that modulate an immune response including stimulating a Th1 pattern of immune activation, cytokine production, NK lytic activity, and B cell proliferation are disclosed. The sequences are also useful as a synthetic adjuvant. | 04-07-2011 |
| 20110059265 | METHOD FOR PRODUCING LAYERED MATERIALS USING LONG-LIVED PHOTO-INDUCED ACTIVE CENTERS - The invention relates to a method for applying a photo-activated layered polymer coating to a substrate material in which one or more layers do not contain photoinitiator, or are not exposed to initiating light, but cure due to migration of cationic active centers. At least two separate monomer layers are applied to the substrate material. At least one of the monomer layers includes a photoinitiator capable of producing cationic active centers. The at least one layer including the photoinitiator is exposed to a source of UV radiation at a desired wavelength forming cationic active centers. The at least two separate monomer layers react in a polymerization reaction forming a cured layered material. The cationic active centers of the exposed monomer layer migrate to the unexposed layer such that both layers cure via the polymerization reaction. | 03-10-2011 |
| 20110054247 | METHODS FOR CLONING FERRETS AND TRANSGENIC FERRET MODELS FOR DISEASES - The invention provides a transgenic Mustelidae in which a gene associated with a human disease or condition comprises a targeted genetic modification, and uses thereof. Also provided is a method to cryopreserve Mustelidae embryos or cells, and to enhance the number of live offspring from cryopreserved Mustelidae embryos. | 03-03-2011 |
| 20110033421 | METHODS RELATED TO IMMUNOSTIMULATORY NUCLEIC ACID-INDUCED INTERFERON - Methods and compositions are provided for extending the clinical utility of IFN-α in the treatment of a variety of viral and proliferative disorders. Among other aspects, the invention provides methods which increase the efficacy of IFN-α treatment and reduce IFN-α treatment-related side effects. In addition, methods are provided for supporting the survival and for activating natural interferon producing cells (IPCs) in vitro without exogenous IL-3 or GM-CSF. The invention is based on the discovery that certain CpG and non-CpG ISNAs promote survival and stimulation of IPCs. | 02-10-2011 |
| 20100330630 | SPRAY DRIED MICROBES AND METHODS OF PREPARATION AND USE - The invention provides spray-dried preparations of microbes and methods of using those microbes. | 12-30-2010 |
| 20100291673 | ALTERNATIVE EXPORT PATHWAYS FOR VECTOR EXPRESSED RNA INTERFERENCE - The present invention is directed to nucleic acid molecules containing a loop sequence designed to circumvent exportin-5 mediated export, and methods using these novel molecules. | 11-18-2010 |
| 20100248263 | BIOMARKERS ASSOCIATED WITH AGE-RELATED MACULAR DEGENERATION - The invention relates to proteins associated with age-related macular degeneration (AMD). These proteins, which are present in blood, are expressed in individuals with AMD at either elevated or reduced levels compared to healthy individuals. The invention provides methods for diagnosing AMD. The invention provides methods for assessing the efficacy of treatment of AMD. The invention provides methods for monitoring the progression of AMD. | 09-30-2010 |
| 20100240612 | Prenylated Bisphosphonates as Anti-tuberculosis Agents - The invention provides methods to treat a mycobacterium infection and methods to inhibit mycobacterial polyprenyl pyrophosphate synthesis with a compound of formula I. The invention also provides novel compounds of formula I as well as salts and prodrugs thereof. | 09-23-2010 |
| 20100235936 | ZINC-FINGER NUCLEASE AND RNA INTERFERENCE MEDIATED INACTIVATION OF VIRAL GENOMES - Embodiments of the present invention provide methods for targeted inactivation of viral genomes. In one embodiment, zinc-finger proteins in which DNA binding sites are altered such that they recognize and bind different, desired DNA sequences contained in hepatitis B virus (HBV) and that include nuclease domains are used for inactivation. Other embodiments for targeted inactivation of viral genomes use small nucleic acid molecules, such as short micro-RNA molecules or short hairpin RNA molecules capable of mediating RNA interference (RNAi) against the hepatitis B virus. | 09-16-2010 |
| 20100227392 | Use of RPA32, RPA4, and RPA4/RPA32 Hybrid Polypeptides and Polynucleotides for Assessing and Modulating Cell Proliferation - Disclosed are polynucleotides and polypeptides that are useful for assessing and modulating cell proliferation. The polynucleotides may comprise coding regions for RPA4 and RPA4/RPA32 hybrid polypeptides. The polynucleotides may be used in gene vectors for modulating cell proliferation in a patient in need thereof. Diagnostic methods related to assaying RPA4 expression in test samples in order to detect proliferating or cancerous cells also are disclosed. | 09-09-2010 |
| 20100226929 | Direct Oxidation of Calcium/Calmodulin Dependent Protein Kinase II and Associated Diagnostic and Therapeutic Methods - Calcium/calmodulin dependent protein kinase II (CaMKII) has been found to be directly oxidized, and direct oxidation of CaMKII was observed to result in calcium independent activation of CaMKII. Antibodies that bind specifically to oxidized forms of CaMKII (oxCaMKII) were generated and were utilized to detect oxCaMKII in blood from: (1) mice with cancer; (2) mice with a knock out of the gene encoding methionine sulfoxide reductase; (3) mice injected with angiotensin II; (4) mice injected with bacterial endotoxin; (5) mice fed a pro-oxidant (ketogenic) diet; and (6) mice with cancer that had been treated with experimental therapy. | 09-09-2010 |
| 20100179330 | Methods for the Preparation of Thiazolidinethione Indene-Based Chiral Auxiliaries - Methods for the preparation of indene-based thiazolidinethiones are provided comprising contacting 1-amino-2,3-dihydro-1H-inden-2-ol, or a substituted derivative thereof, with an acid under suitable reaction conditions to provide a first intermediate; and contacting the first intermediate with an alkali xanthate in the presence of an alkali hydroxide under suitable reaction conditions to provide a compound of formula (III), | 07-15-2010 |
| 20100179217 | THERAPEUTIC COMPOUNDS - The invention provides novel compounds of formula I: that are opioid receptor ligands. The invention also provides pharmaceutical compositions comprising such compounds as well as methods for treating diseases associated with opioid receptor function by administering such compounds to a mammal in need of treatment. Compounds of the invention are useful to modulate (e.g. agonize or antagonize) opioid receptor function. | 07-15-2010 |
| 20100148154 | APPARATUS AND SEMICONDUCTOR CO-CRYSTAL - The invention provides a method to enforce face-to-face stacking of organic semiconductors in the solid state that employs semiconductor co-crystal formers (SCCFs), to align semiconductor building blocks (SBBs). Single-crystal X-ray analysis reveals π-orbital overlap optimal for organic semiconductor device applications. | 06-17-2010 |
| 20100144026 | siRNA-mediated gene silencing with viral vectors - The present invention is directed to viral vectors encoding small interfering RNA molecules (siRNA) targeted against a gene of interest, and methods of using these viral vectors. | 06-10-2010 |
| 20100081706 | IMMUNOMODULATORY OLIOGONUCLEOTIDES AND METHODS OF USE THEREFOR - The present invention is drawn a new class of oligodeoxynucleotides (ODNs) that inhibit ODN-activation of Toll-like receptor (TLR) 9. Particular 4-5 base extensions at the 5′ and of the previously described core inhibitory ODN sequence enhances their inhibitory activity against human cells expressing human TLR9. Methods of use also are provided. | 04-01-2010 |
| 20100076061 | REPEATED ADMINISTRATION OF LENTIVIRAL VECTORS TO RESPIRATORY CELLS - The invention provides methods for administering lentiviral vectors to the respiratory system of a patient to treat a disease. | 03-25-2010 |
| 20100028231 | SYNTHESIS AND USE OF NANOCRYSTALLINE ZEOLITES - Embodiments of the present invention relate to a method for synthesizing nanocrystalline zeolites, the method comprising contacting starting products that comprise a solvent, a silicon source, a cation base, an organic template, and an aluminum source, or any combination thereof sufficient to produce a zeolite gel by hydrolysis, heating the zeolite gel sufficient to produce a first batch of zeolite crystals and a first clear solution, separating the first batch of zeolite crystals from the first clear solution, heating the first clear solution sufficient to produce a second batch of zeolite crystals and second clear solution and separating the second batch of zeolite crystals from the second clear solution. In addition, embodiments relate to a method of using nanocrystalline zeolites, the method comprising contacting a nanocrystalline zeolite with a reductant sufficient to produce a nanocrystalline zeolite with adsorbed reductant and exposing the nanocrystalline zeolite with adsorbed reductant to reactant gases sufficient to obtain reaction products and the nanocrystalline zeolite. | 02-04-2010 |
| 20100010185 | MODIFIED POLYDICYCLOPENTADIENES - The present invention provides novel, modified polydicyclopentadienes and methods to prepare modified polydicyclopentadienes. The modified polydicyclopentadienes prepared by the methods of the invention are useful in many applications including new and useful solid phases for chromatography. | 01-14-2010 |
| 20090299102 | APPARATUS AND METHOD FOR CARRYING OUT MULTIPLE REACTIONS - The invention provides methods and an apparatus useful for site-isolating reagents or catalysts during chemical reactions. The methods and apparatus are useful for carrying out cascade or domino reactions. | 12-03-2009 |
| 20090291150 | METHOD AND COMPOSITIONS FOR TREATING AND PREVENTING SEIZURES BY MODULATING ACID-SENSING ION CHANNEL ACTIVITY - This invention provides novel methods and compositions for treating and preventing seizures by administration of ASIC1a receptor activating compounds. A novel method of assaying ASIC1a receptor activating compounds is included in the present invention. According to the invention applicants have demonstrated that seizure duration, intensity, and progression may be modulated by administration of an ASIC1a receptor activator which acts to increase the endogenous activity of ASIC1a receptors to mediate the effects of low pH in the CNS. The inventors have also found that the ASIC1a receptor activator may prevent such seizures altogether. | 11-26-2009 |
| 20090258822 | Diagnosis and Treatment of Age-Related Macular Degeneration - The invention relates to Factor H gene polymorphisms and haplotypes associated with an elevated or a reduced risk of AMD. The invention provides methods and reagents for diagnosis and treatment of AMD. | 10-15-2009 |
| 20090257723 | FIBERSCOPES AND FIBER BUNDLES - An elongate imaging fiber bundle may include a plurality of elongate optical fibers coherently arranged in the bundle, the plurality including peripheral fibers at a periphery of the bundle and deep fibers deep to the peripheral fibers, and a coating surrounding the plurality of fibers. An exposed length of the bundle, intermediate the bundle's proximal and distal ends, may be chemically etched to be denuded of the coating, and peripheral fibers are so severed as to permit injection of light into the peripheral fibers at the exposed length. A fiberscope may include a fiber bundle having an exposed length that is denuded of the coating, and peripheral fibers are so severed in the exposed length as to permit injection of light into the peripheral fibers at the exposed length, and a light source so positioned with respect to the exposed length of the bundle as to inject light into the peripheral fibers at the exposed length. | 10-15-2009 |
| 20090247451 | Therapeutic Compositions for Age-Related Macular Degeneration - The invention relates to Factor H gene polymorphisms and haplotypes associated with an elevated or a reduced risk of AMD. The invention provides methods and reagents for diagnosis and treatment of AMD. | 10-01-2009 |
| 20090241206 | METHODS FOR CLONING FERRETS AND TRANSGENIC FERRET MODELS FOR DISEASES - The invention provides a transgenic Mustelidae in which a gene associated with a human disease or condition comprises a targeted genetic modification, and uses thereof. Also provided is a method to cryopreserve Mustelidae embryos or cells, and to enhance the number of live offspring from cryopreserved Mustelidae embryos. | 09-24-2009 |
| 20090202575 | IMMUNOSTIMULATORY NUCLEIC ACID MOLECULES - Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed. | 08-13-2009 |
| 20090191188 | IMMUNOSTIMULATORY NUCLEIC ACIDS - The invention relates to immunostimulatory nucleic acid compositions and methods of using the compositions. The T-rich nucleic acids contain poly T sequences and/or have greater than 25% T nucleotide residues. The TG nucleic acids have TG dinucleotides. The C-rich nucleic acids have at least one poly-C region and/ore greater than 50% c nucleotides. These immunostimulatory nucleic acids function in a similar manner to nucleic acids containing CpG motifs. The invention also encompasses preferred CpG nucleic acids. | 07-30-2009 |
| 20090124542 | METHODS AND REAGENTS FOR TREATMENT AND DIAGNOSIS OF AGE-RELATED MACULAR DEGENERATION - The invention relates to Factor H gene polymorphisms and haplotypes associated with an elevated or a reduced risk of AMD. The invention provides methods and reagents for diagnosis and treatment of AMD. | 05-14-2009 |
| 20090105169 | ALLELE-SPECIFIC SILENCING OF DISEASE GENES - The present invention is directed to small interfering RNA molecules (siRNA) targeted against an allele of interest, and methods of using these siRNA molecules. | 04-23-2009 |
| 20090088466 | OPIOID RECEPTOR LIGANDS - The invention provides novel compounds of formula (I), (II), (III), and (IV). The invention also provides pharmaceutical compositions comprising such compounds as well as methods for treating diseases associated with opioid receptor function by administering such compounds to an animal in need of treatment. The invention also provides therapeutic methods for the use of compounds of formula (V), as well as methods for treating diseases by administering such compounds. | 04-02-2009 |
| 20080318264 | Biomarkers Associated With Age-Related Macular Degeneration - The invention relates to proteins associated with age-related macular degeneration (AMD). These proteins, which are present in blood, are expressed in individuals with AMD at either elevated or reduced levels compared to healthy individuals. The invention provides methods for diagnosing AMD. The invention provides methods for assessing the efficacy of treatment of AMD. The invention provides methods for monitoring the progression of AMD. | 12-25-2008 |
| 20080305273 | METHOD OF APPLYING POLYMER COATING TO A SUBSTRATE - An object of complex three-dimensional configuration, such as an automotive vehicle body, is coated with a combination of a coating formulation and a photoactivated mixture containing active centers that have been produced prior to application. The two liquids can be intimately mixed prior to application to the object, or the coating formulation can be applied prior to the application of the photoactivated mixture. The coating formulation is cured by the active centers that have been produced prior to application. | 12-11-2008 |
| 20080280825 | Protective complement proteins and age-related macular degenration - Methods for identifying a subject at risk for developing AMD are disclosed. The methods include identifying specific protective or risk polymorphisms or genotypes from the subject's genetic material. Therapeutic compositions and methods are also provided for delaying the progression or onset of the development of AMD in a subject, including treating a subject having signs and/or symptoms of AMD or who has been diagnosed with AMD. | 11-13-2008 |
| 20080274989 | Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof - The present invention is directed to small interfering RNA molecules (siRNA) targeted against nucleic acid sequence that encodes huntingtin or ataxin-1, and methods of using these siRNA molecules. | 11-06-2008 |
| 20080274453 | Diagnostics and therapeutics for macular degeneration - The invention relates to diagnostics and therapeutics and animal models for macular degeneration, specifically as they relate to the association described herein between macular degeneration and arterial wall disruptive disorders. In one embodiment, the invention provides kits and methods for diagnosing macular degeneration comprising identifying a marker for an arterial wall disruptive disorder, including an aneurysm. In one embodiment, the invention provides therapeutics for treating macular degeneration comprising delivering to a subject an agent useful for treating an arterial wall disruptive disorder, including an aneurysm. | 11-06-2008 |
| 20080249050 | Compounds and methods to enhance rAAV transduction - Agents and methods to alter rAAV transduction are provided. | 10-09-2008 |
